Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA012800 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA012800, RRID:AB_1855330
- Product name
- Anti-PLD3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human PLD3, Gene description: phospholipase D family, member 3, Alternative Gene Names: HU-K4, Validated applications: IHC, WB, Uniprot ID: Q8IV08, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Structural analysis of PLD3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation
Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer
Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease
PLD3 affects axonal spheroids and network defects in Alzheimer’s disease
AMPylation profiling during neuronal differentiation reveals extensive variation on lysosomal proteins
PLD3 Rare Variants Identified in Late-Onset Alzheimer’s Disease Affect Amyloid-β Levels in Cellular Model
Analysis of novel endosome-to-Golgi retrieval genes reveals a role for PLD3 in regulating endosomal protein sorting and amyloid precursor protein processing
PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains
Roske Y, Cappel C, Cremer N, Hoffmann P, Koudelka T, Tholey A, Heinemann U, Daumke O, Damme M
Nucleic Acids Research 2024;52(1):370-384
Nucleic Acids Research 2024;52(1):370-384
Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer
Lastwika K, Kunihiro A, Solan J, Zhang Y, Taverne L, Shelley D, Rho J, Randolph T, Li C, Grogan E, Massion P, Fitzpatrick A, MacPherson D, Houghton A, Lampe P
Science Translational Medicine 2023;15(678)
Science Translational Medicine 2023;15(678)
Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease
Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue M, Schultz D, Coyne T, Charidimou A, Schrag M
Nature Communications 2023;14(1)
Nature Communications 2023;14(1)
PLD3 affects axonal spheroids and network defects in Alzheimer’s disease
Yuan P, Zhang M, Tong L, Morse T, McDougal R, Ding H, Chan D, Cai Y, Grutzendler J
Nature 2022;612(7939):328-337
Nature 2022;612(7939):328-337
AMPylation profiling during neuronal differentiation reveals extensive variation on lysosomal proteins
Becker T, Cappel C, Di Matteo F, Sonsalla G, Kaminska E, Spada F, Cappello S, Damme M, Kielkowski P
iScience 2021;24(12):103521
iScience 2021;24(12):103521
PLD3 Rare Variants Identified in Late-Onset Alzheimer’s Disease Affect Amyloid-β Levels in Cellular Model
Tan M, Li J, Ma F, Zhang X, Zhao Q, Cao X
Frontiers in Neuroscience 2019;13
Frontiers in Neuroscience 2019;13
Analysis of novel endosome-to-Golgi retrieval genes reveals a role for PLD3 in regulating endosomal protein sorting and amyloid precursor protein processing
Mukadam A, Breusegem S, Seaman M
Cellular and Molecular Life Sciences 2018;75(14):2613-2625
Cellular and Molecular Life Sciences 2018;75(14):2613-2625
PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains
Satoh J, Kino Y, Yamamoto Y, Kawana N, Ishida T, Saito Y, Arima K
Alzheimer's Research & Therapy 2014;6(5-8)
Alzheimer's Research & Therapy 2014;6(5-8)
No comments: Submit comment
No validations: Submit validation data